An evaluation of recaticimab for the treatment of hypercholesterolemia

Expert Opinion on Biological Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 17, 2025

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, by preventing the degradation of LDL receptors, either through interference in binding PCSK9 to receptors or silencing at a molecular level, have revolutionized lipid-lowering treatment and offer opportunity further improve clinical outcomes for patients with hypercholesterolemia. We discuss role as therapeutic target hypercholesterolemia, describe pharmacodynamics, pharmacokinetics, metabolism recaticimab, report recent trials this 'humanized' IgG1 monoclonal antibody (mAb) against PCSK9. Recaticimab has high affinity that confers prolonged duration action. durably decreases LDL-cholesterol, non-HDL-cholesterol apoB, but can also lower Lp(a). may advantages over current mAbs use terms its long half-life, dosing interval up 12 weeks, potentially cost, however, long-term concerns regarding immunogenicity remain. Longer-term studies variety more diverse patient cohorts will be needed evaluate efficacy, safety, durability recaticimab ascertain best schedule cardiovascular outcome studies.

Язык: Английский

American Society for Preventive Cardiology 2024 Cardiovascular Disease Prevention: Highlights and Key Sessions

American Journal of Preventive Cardiology, Год журнала: 2024, Номер 21, С. 100919 - 100919

Опубликована: Дек. 15, 2024

Язык: Английский